The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19 by Carr, Anitra C & Rowe, Sam
nutrients
Editorial
The Emerging Role of Vitamin C in the Prevention
and Treatment of COVID-19
Anitra C. Carr 1,* and Sam Rowe 2,3
1 Nutrition in Medicine Research Group, Department of Pathology & Biomedical Science, University of Otago,
Christchurch 8011, New Zealand
2 Intensive Care Department, Newham University Hospital, Barts NHS Trust, London E13 8SL, UK;
sam.rowe2@nhs.net
3 Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
* Correspondence: anitra.carr@otago.ac.nz; Tel.: +64-3364-0649
Received: 15 October 2020; Accepted: 21 October 2020; Published: 27 October 2020


Abstract: Investigation into the role of vitamin C in the prevention and treatment of pneumonia and
sepsis has been underway for many decades. This research has laid a strong foundation for translation
of these findings into patients with severe coronavirus disease (COVID-19). Research has indicated
that patients with pneumonia and sepsis have low vitamin C status and elevated oxidative stress.
Administration of vitamin C to patients with pneumonia can decrease the severity and duration of
the disease. Critically ill patients with sepsis require intravenous administration of gram amounts of
the vitamin to normalize plasma levels, an intervention that some studies suggest reduces mortality.
The vitamin has pleiotropic physiological functions, many of which are relevant to COVID-19.
These include its antioxidant, anti-inflammatory, antithrombotic and immuno-modulatory functions.
Preliminary observational studies indicate low vitamin C status in critically ill patients with COVID-19.
There are currently a number of randomized controlled trials (RCTs) registered globally that are
assessing intravenous vitamin C monotherapy in patients with COVID-19. Since hypovitaminosis C
and deficiency are common in low–middle-income settings, and many of the risk factors for vitamin
C deficiency overlap with COVID-19 risk factors, it is possible that trials carried out in populations
with chronic hypovitaminosis C may show greater efficacy. This is particularly relevant for the
global research effort since COVID-19 is disproportionately affecting low–middle-income countries
and low-income groups globally. One small trial from China has finished early and the findings
are currently under peer review. There was significantly decreased mortality in the more severely
ill patients who received vitamin C intervention. The upcoming findings from the larger RCTs
currently underway will provide more definitive evidence. Optimization of the intervention protocols
in future trials, e.g., earlier and sustained administration, is warranted to potentially improve its
efficacy. Due to the excellent safety profile, low cost, and potential for rapid upscaling of production,
administration of vitamin C to patients with hypovitaminosis C and severe respiratory infections,
e.g., COVID-19, appears warranted.
Keywords: vitamin C; ascorbate; ascorbic acid; COVID-19; pneumonia; sepsis; acute respiratory
distress syndrome; randomized controlled trials; low-middle-income
For a quarter of a century, it has been known that critically ill patients, including those with
sepsis and multiple organ failure, have very low vitamin C status [1–3]. It has also been demonstrated
that these critically ill patients have higher requirements for vitamin C, with gram doses required
to normalize their blood levels [4,5], 20–30 times more than is required for the general population.
Despite these findings, critically ill patients with sepsis continue to be administered milligram amounts
of vitamin C, which is insufficient to replete their vitamin C status [6]. In 2014, Dr Fowler and colleagues
Nutrients 2020, 12, 3286; doi:10.3390/nu12113286 www.mdpi.com/journal/nutrients
Nutrients 2020, 12, 3286 2 of 8
published the findings of a small clinical trial which indicated that intravenous administration of
gram amounts of vitamin C to patients with sepsis could improve organ failure scores and decrease
markers of inflammation (C-reactive protein) and tissue damage (thrombomodulin) [7]. In a larger
randomized controlled trial (RCT) of septic patients with acute respiratory distress syndrome (ARDS),
the CITRIS-ALI trial, intravenous administration of 200 mg/kg/d of vitamin C for 4 days resulted in a
28 day mortality of 30% relative to 46% in the placebo group (p = 0.03) and a hazard ratio (HR) of 0.55
(95% CI, 0.33–0.90, p = 0.01) [8]. The number of intensive care unit (ICU)- and hospital-free days was
also significantly higher in the vitamin C group.
Administration of vitamin C late in the disease process, e.g., when ARDS has developed,
likely attenuates its effectiveness. Earlier clinical trials have indicated that administration of vitamin C
to patients with pneumonia can decrease the severity of the respiratory symptoms, particularly of the
most severely ill patients, and the duration of hospital stay [9,10]. Thus, administration of vitamin C
earlier in the respiratory infection process may prevent its progression to sepsis [11]. Survival data
from the CITRIS-ALI trial has indicated that the effect of vitamin C on survival is most apparent
during the 4 day infusion period [12]. Furthermore, pharmacokinetic research has indicated that upon
cessation of vitamin C infusion, the vitamin C status of some patients returns to their low pre-infusion
levels [5]. These findings call to sustained administration of the vitamin in the ICU. This will likely also
improve the long-term outcomes of the patients, particularly if they continue to take the vitamin orally
following discharge from ICU, due to its important roles in immunological function and in multiple
organ systems [11].
Earlier this year, Dr Fowler and colleagues published a review on the emerging role of vitamin C
as a treatment for sepsis [13]. In this review, they summarised the current state of knowledge around
its pleiotropic physiological functions in sepsis. These include its roles as an antioxidant, a cofactor for
the synthesis of vasopressors (norepinephrine and vasopressin), and roles in leukocyte and platelet
functions, and endothelial and epithelial cell integrity. In the face of the current severe acute respiratory
syndrome coronavirus (SARS-CoV-2) pandemic, this review has been very timely, with sepsis being a
significant complication of severe coronavirus disease (COVID-19) [14].
Many of the functions of vitamin C appear relevant to COVID-19-related sepsis and ARDS.
For example, recent research has uncovered a connection between SARS-CoV-2 infection and depleted
levels of the antiviral cytokine interferon [15], and a negative association between interferon levels and
disease severity [16,17]. Of note, vitamin C has been shown to augment interferon levels in animal
models of viral infection [18,19]. Another characteristic of severe COVID-19 is elevated inflammatory
markers and this can present as a ‘cytokine storm’ in some cases [14]. Vitamin C has anti-inflammatory
and antioxidant activities which can potentially counteract this phenomenon [13]. Preliminary evidence
from a small COVID-19 trial indicates that administration of intravenous vitamin C can significantly
decrease IL-6 levels by day 7 of infusion [20].
Other common complications of COVID-19 are coagulopathy and microthrombi formation [14],
which is likely a major component of COVID-19 lung pathology [21]. Early injection of vitamin C
has been shown to prevent microthrombi formation and capillary plugging [22], and a case series
has shown decreased D-dimer levels in COVID-19 patients who were administered intravenous
vitamin C [23]. Neutrophil extracellular traps (NETs) have been implicated in COVID-19-related
thrombotic complications [24,25]. Previous research has indicated that vitamin C administration can
attenuate NETs in sepsis models [26], and post-hoc analysis of the CITRIS-ALI trial indicated decreased
circulating cell-free DNA 48 h after administration of intravenous vitamin C [27]. Neutrophil-derived
oxidative stress is believed to induce tissue damage in COVID-19 [28,29]. Patients with pneumonia and
sepsis have significantly elevated oxidative stress markers relative to other critically ill patients [30,31],
and early studies indicated that administration of vitamin C and other antioxidants to patients with
septic shock and ARDS stabilized oxidative stress markers and improved cardiovascular parameters
and survival [32,33].
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In March, the World Health Organization published a coordinated global research roadmap for
the 2019 novel coronavirus in which they identified a number of scientific knowledge gaps around
determination of interventions that improve the clinical outcome of COVID-19-infected patients,
including optimal selection of strategies for supportive care of seriously ill patients [34]. Of note,
vitamin C was highlighted as an adjunctive intervention with biologic plausibility. Meta-analyses
of relevant clinical trials have indicated that administration of vitamin C to critically ill patients can
decrease the duration of mechanical ventilation and length of stay in ICU [35,36]. This is pertinent
given global shortages of ICU capacity and may be particularly important for resource-limited settings
such as those found in low–middle-income countries (LMICs) [37]. Of note, vitamin C production
could be rapidly up-scaled globally, unlike many of the novel pharmacological treatments, some of
which, e.g., remdesivir, have global shortages.
It is noteworthy that a majority of the top 10 countries with the highest COVID-19 case-loads are
LMICs. In a recent review we highlighted the high prevalence of hypovitaminosis C and deficiency in
LMICs (Figure 1) [38]. Furthermore, many of the risk factors for COVID-19 overlap with risk factors
for vitamin C deficiency, such as poverty [39,40]. People who already have hypovitaminosis C are
particularly susceptible to developing outright deficiency, and ergo more likely to respond to vitamin C
administration. Therefore, the baseline vitamin C status of people with COVID-19 will likely affect
their outcomes and their response to intervention [41,42].
Nutrients 2020, 12, x FOR PEER REVIEW 3 of 7 
including optimal selection of strategies for supportive care of seriously ill patients [34]. Of note, 
vitamin C was highlighted as an adjunctive intervention ith biologic plausibility. Meta-analyses of 
relevant clinical trials have indicated that ad inistration of vita in C to critically ill patients can 
decrease the duration of mechanical ventilation and length of stay in ICU [35,36]. This is pertinent 
given global shortages of ICU capacity and may be particularly important for resource-limited 
settings such as those found in low–middle-income countries (LMICs) [37]. Of note, vitamin C 
production could be rapidly up-scaled globally, unlike many of the novel pharmacological 
treatments, some of which, e.g., remdesivir, have global shortages. 
It is noteworthy that a majority of the top 10 countries with the highest COVID-19 case-loads are 
LMICs. In a recent review we highlighted the high prevalence of hypovitaminosis C and deficiency 
in LMICs (Figure 1) [38]. Furthermore, many of the risk factors for COVID-19 overlap with risk factors 
for vitamin C deficiency, such as poverty [39,40]. People who already have hypovitaminosis C are 
particularly susceptible to developing outright deficiency, and ergo more likely to respond to vitamin 
C administration. Therefore, the baseline vitamin C status of people with COVID-19 will likely affect 
their outcomes and their response to intervention [41,42].  
Figure 1. Summary of global vitamin C status (A) and intake (B) and prevalence of hypovitaminosis 
(C) and vitamin C deficiency (D). HIC—high-income countries; LMICs—low-middle-income
countries. Hypovitaminosis C, <23 µmol/L; vitamin C deficiency, <11 µmol/L. Numbers above bars
indicate the total number of individuals assessed. Data from [38].
As yet, there have been few publications reporting on the vitamin C status of patients with 
COVID-19. An observational study in the USA has indicated a mean vitamin C status of 22 ± 18 
µmol/L in a cohort of 21 critically ill patients with COVID-19 [43], which is comparable to other 
studies of critically ill patients with sepsis [11]. An earlier case series from Spain indicated the absence 
of any detectable vitamin C in 17 of a cohort of 18 COVID-19 patients with ARDS [44]. However, the 
veracity of the methodology used to assess the vitamin C status of the patients was not clear, so the 
values could be artifactually low [45].  
Figure 1. Summary of global vitamin C status (A) and intake (B) and prevalence of hypovitaminosis
(C) and vitamin C deficiency (D). HIC—high-income countries; LMICs—low-middle-income countries.
Hypovitaminosis C, <23 µmol/L; vitamin C deficiency, <11 µmol/L. Numbers above bars indicate the
total number of individuals assessed. Data from [38].
As yet, there have be n few publications reporting on the vitamin C status of patients with
COVID-19. An observational study in the USA has indicated mean vitamin C status of 22 ± 18 µmol/L
Nutrients 2020, 12, 3286 4 of 8
in a cohort of 21 critically ill patients with COVID-19 [43], which is comparable to other studies of
critically ill patients with sepsis [11]. An earlier case series from Spain indicated the absence of any
detectable vitamin C in 17 of a cohort of 18 COVID-19 patients with ARDS [44]. However, the veracity
of the methodology used to assess the vitamin C status of the patients was not clear, so the values
could be artifactually low [45].
There are a number of clinical trials registered globally assessing intravenous vitamin
C monotherapy in COVID-19 patients (Table 1). The first trial off the ground was in
Hubei, China (NCT04264533) [46]. In this trial the investigators planned to treat 140 patients with a
placebo control or intravenous vitamin C at a relatively high dose of 24 g/day for 7 days, and assess
requirements for mechanical ventilation and vasopressor drugs, organ failure scores, ICU length of
stay and mortality. A preprint of the findings of 54 patients from this trial is currently under peer
review [15]. Although the investigators reported no differences between the treatment and placebo
groups for the above outcomes, when a subgroup of the most severely ill patients (SOFA scores ≥ 3)
was assessed, a significant decrease in ICU and hospital mortality was observed in the vitamin C
group—18% vs. 50% in the placebo group (HR 0.2, 95% CI 0.1–0.9, p = 0.03). Unfortunately, the baseline
vitamin C status of the patients was not reported.
The USA currently has the highest number of COVID-19 cases globally, however despite this,
there are only a couple of small intravenous vitamin C monotherapy and COVID-19 trials registered in
the USA (NCT04344184 and NCT04363216). A trial at the Cleveland Clinic is assessing oral vitamin C
with and without zinc (NCT04342728). However, due to the pharmacokinetics of enteral and parenteral
vitamin C differing dramatically, and the higher requirement for vitamin C during respiratory infections,
oral vitamin C may not be as efficacious as intravenous vitamin C [42]. As such, future meta-analyses
of vitamin C and COVID-19 clinical trials should include subgroup analyses of studies comprising
intravenous vs. oral vitamin C. Furthermore, subgroup analysis of low vitamin C populations could
also be carried out as RCT findings will likely vary depending on the country and hence the baseline
vitamin C status of the population in which the study was carried out [47]. In populations with a high
prevalence of chronic hypovitaminosis C, vitamin C intervention may show greater efficacy.
Overall, vitamin C exhibits plausible mechanisms of action that are of relevance to severe respiratory
infection, including antioxidant, anti-inflammatory, antithrombotic, and immuno-modulatory functions.
Based on the findings from clinical trials of patients with pneumonia and sepsis, and preliminary
observational and interventional studies of COVID-19 patients, it is likely that vitamin C administration
will improve outcomes in COVID-19. The upcoming findings from the larger RCTs currently underway
(e.g., LOVIT-COVID), including introduction of intravenous vitamin C arms to large adaptive trials
(e.g., REMAP-CAP; NCT02735707), will provide more definitive evidence. Some of these trials
(e.g., LOVIT-COVID) are also examining the longer-term quality of life effects of short-term vitamin C
administration. Optimization of the intervention protocols in future trials, e.g., earlier and sustained
administration, is warranted to potentially improve its efficacy. Due to the excellent safety profile,
low cost, and potential for rapid upscaling of production, administration of vitamin C to patients with
hypovitaminosis C and severe respiratory infections, e.g., COVID-19, appears warranted.
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Table 1. Summary of registered intravenous vitamin C (IVC) monotherapy and COVID-19 trials globally.
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